Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin system in early postmenopausal women.
J Clin Endocrinol Metab
; 89(1): 188-92, 2004 Jan.
Article
em En
| MEDLINE
| ID: mdl-14715848
We investigated the serum levels of both receptor activator of nuclear factor kappaB ligand (RANKL) and its decoy receptor osteoprotegerin (OPG) in postmenopausal healthy women after a 1-yr therapy with genistein, (n = 30; 54 mg/d), hormone replacement therapy (n = 30; 1 mg/d 17beta-estradiol combined with norethisterone acetate) and placebo (n = 30). By comparison with placebo, the soluble RANKL (sRANKL)/OPG ratio was lower in the genistein group (-69 +/- 7%; P < 0.01 vs. placebo 81 +/- 24%) and in hormone replacement therapy-treated women (-11 +/- 2%; P < 0.01 vs. placebo). A positive correlation (r = 0.63; P < 0.01) was found between 1-yr percentage change in sRANKL/OPG ratio and 1-yr change in urinary deoxypyridinoline, a bone resorption marker. A negative correlation was observed between 1-yr percentage change in sRANKL/OPG ratio and 1-yr change in femoral neck bone mineral density (r = -0.7; P < 0.01). Our findings suggest that the sRANKL-OPG system may mediate the beneficial effects of genistein on bone remodeling in postmenopausal women.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Glicoproteínas de Membrana
/
Glicoproteínas
/
Proteínas de Transporte
/
Receptores Citoplasmáticos e Nucleares
/
Pós-Menopausa
/
Genisteína
/
Noretindrona
Tipo de estudo:
Clinical_trials
Limite:
Female
/
Humans
/
Middle aged
Idioma:
En
Ano de publicação:
2004
Tipo de documento:
Article